KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.

Marc P Bonaca, Javid J Moslehi, Jonathan A Ledermann, Elisabete Michelon, Caimiao Wei, Michael Moran, Bradley J Monk, Eric Pujade-Lauraine

Oncologist 28(10) e977-e980

PMID37665777
PMCIDPMC10546816
DOI10.1093/oncolo/oyad213
发表日期2023-09-04
入排依据:The report is from a Phase III randomized trial in oncology with a drug intervention, but the abstract focuses exclusively on cardiac safety (LVEF) data and does not report any time-to-event efficacy endpoint (e.g., OS, PFS).
摘要

摘要

UNLABELLED: In the phase III JAVELIN Ovarian 200 trial, 566 patients with platinum-resistant/refractory ovarian cancer were randomized 1:1:1 to receive avelumab alone, avelumab plus pegylated liposomal doxorubicin (PLD), or PLD alone. Cardiac monitoring was included for all patients. We report left ventricular ejection fraction (LVEF) data from the trial. Grade ≥3 cardiac adverse events (AEs) occurred in 4 (2.1%), 1 (0.5%), and 0 patients in the avelumab, combination, and PLD arms, respectively. LVEF decreases of ≥10% to below institutional lower limit of normal at any time during treatment were observed in 1 (0.8%), 3 (1.9%), and 2 (1.5%) patients, respectively; 4 had subsequent assessments, and these showed transient decreases. No patient had a cardiovascular AE related to LVEF decrease. This analysis is, to our knowledge, the first analysis of LVEF in patients receiving immune checkpoint inhibitors. CLINICALTRIALS.GOV IDENTIFIER: NCT02580058.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。